BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 05, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stalevo levodopa/carbidopa/entacapone regulatory update

FDA plans to review the safety of Stalevo levodopa/carbidopa/entacapone based on data from the four-year Phase III STRIDE-PD trial that showed an increased incidence of prostate cancer in patients receiving the drug compared to control. Specifically, nine (3.7%) out of 245 males...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >